GlobeNewswire by notified

Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease

Share

Mechelen, Belgium; 22 November2021, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announces completion of recruitment in the MANGROVE Phase 2 trial with investigational CFTR inhibitor GLPG2737 in patients with autosomal dominant polycystic kidney disease (ADPKD).

MANGROVE is a randomized, double-blind, placebo-controlled trial evaluating a once-daily oral dose of GLPG2737 (NCT04578548). The drug candidate or placebo is administered for 52 weeks, followed by an open-label extension period of 52 weeks, in 66 ADPKD patients with rapidly progressing disease. Patients are randomized in a 2:1 ratio of treatment to placebo. Primary objectives of the trial are to assess the effect on growth of total kidney volume over 52 weeks compared to placebo as well as overall safety and tolerability. Secondary objectives include renal function, pharmacokinetics, and pharmacodynamics. Recruitment for the MANGROVE trial was conducted in 7 countries in Europe.

GLPG2737 is a CFTR1 inhibitor which was observed to be well tolerated by patients in previous clinical trials. It is hypothesized that inhibition of the CFTR channel might reduce cyst growth and kidney enlargement for patients with ADPKD.

Galapagos expects topline results from the MANGROVE Phase 2 trial in the first half of 2023.

“We thank the ADPKD community for participating in the MANGROVE Phase 2 trial with GLPG2737,” said Dr. Walid Abi-Saab, Chief Medical Officer of Galapagos. “Polycystic kidney disease patients have a real need for new therapy options. We hope to learn in 2023 from this trial what CFTR modulation may be able to achieve against ADPKD, in our mission to bring new medicines to kidney disease patients.”

About ADPKD
Autosomal dominant polycystic kidney disease affects approximately 12.5 million people worldwide and is the fourth leading cause of kidney failure today.2 Typically with this disease, both kidneys enlarge with fluid-filled cysts, leading to kidney failure for approximately half of patients by the age of 60 and requiring dialysis and possibly kidney transplantation.3 Patients may also suffer from hypertension, abdominal pain, kidney infections, cyst ruptures, bleeding, and other symptoms impacting quality of life. Other organs may be affected as well. Treatment is aimed at relieving symptoms and controlling the accompanying hypertension. Currently, only one therapy (tolvaptan) is available to slow down the progression of cyst development and renal insufficiency; however, not all patients tolerate this therapy.4

About Galapagos
Galapagos NV discovers, develops, and commercializes small molecule medicines with novel modes of action. Our pipeline comprises discovery through Phase 3 programs in inflammation, fibrosis, and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. More information is available at www.glpg.com.

Contacts

Investors:
Elizabeth Goodwin
VP Investor Relations
+1 781 460 1784

Sofie Van Gijsel
Senior Director Investor Relations
+1 781 296 1143

Sandra Cauwenberghs
Director Investor Relations
+32 495 58 46 63
ir@glpg.com

Media:
Anna Gibbins
Senior Director Therapeutic Areas Communications
+44 7717 801900

Evelyn Fox
Director Executive Communications
+31 65 3591 999
communications@glpg.com

Forward-looking statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements and, therefore, the reader should not place undue reliance on them. These risks, uncertainties and other factors include, without limitation, the risk that ongoing and future clinical studies with GLPG2737 may not be completed in the currently envisaged timelines or at all, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that data from the ongoing and planned clinical research programs may not support registration or further development of GLPG2737 due to safety or efficacy concerns or other reasons), Galapagos' reliance on collaborations with third parties, and that Galapagos’ estimations regarding its GLPG2737 development program, regarding thepotential value of CFTR inhibition as a mechanism to treat ADPKD, and regarding the commercial potential of GLPG2737, may be incorrect, as well as those risks and uncertainties identified in our Annual Report on Form 20-F for the year ended 31 December 2020 and our subsequent filings with the SEC. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The forward-looking statements contained herein are based on management’s current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no commitment to update or publicly release any revisions to forward-looking statements in order to reflect new information or subsequent events, circumstances or changes in expectations.


1 Cystic Fibrosis Transmembrane Conductance Regulator
2 Chebib F.T., Torres V.E. Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2016. Am J Kidney Dis. May 2016, 67 (5) 792-810
3 Parfrey P.S., Bear J.C., Morgan J., Cramer B.C., McManamon P.J., Gault M.H., et al. The diagnosis and prognosis of autosomal dominant polycystic kidney disease. N Engl J Med. 1990;323(16):1085–90
4 Chebib F.T., Perrone R.D., Chapman A.B., Dahl N.K., Harris P.C., Mrug M., et al. A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. JASN. October 2018, 29 (10) 2458-2470

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

AMG Advanced Metallurgical Group N.V. Completes Issuance of $550 Million of Credit Facilities30.11.2021 22:00:00 CET | Press release

Amsterdam, 30November 2021--- AMG Advanced Metallurgical Group N.V. ("AMG", EURONEXT AMSTERDAM: "AMG") is pleased to announce that it has entered into a new $350 million 7-year senior secured term loan B facility ("term loan") and a $200 million 5-year senior secured revolving credit facility ("revolver"). The total facility amount of $550 million replaces AMG’s existing credit facility and extends our term loan maturity from 2025 to 2028 and revolver maturity from 2023 to 2025. AMG will use the proceeds of the new term loan to refinance its existing credit facility. Further strengthening AMG’s commitment to Environmental, Social and Governance ("ESG"), we have embedded annual CO2 intensity reduction targets into the Revolving Credit Facility, making it a Sustainability Linked Loan. Moody's Investors Service ("Moody's") assigned a Ba3 rating to the new senior secured credit facility, affirmed our B2 corporate family rating and changed their outlook to positive from stable. S&P Global R

EPH European Property Holdings Limited (EPH) announces Third Quarter 2021 Financial Update30.11.2021 19:00:00 CET | Press release

30November 2021, Road Town, Tortola, BVI I Ad hoc announcement pursuant to Art. 53 LR In Q3 2021, there were no significant changes in the Company’s financial position and/or structure of its balance sheet in comparison to the published semi-annual report, given that fair value of investment properties was not revaluated as of 30 September 2021. In Q3 2021, the Company demonstrated stable performance compared to the last year. The rental properties continued generating sufficient cash to cover the Company’s operating expenses, service the debt and partially finance its investment program. The net rental income (NRI) increased from US$45.33 mln in the first 9 months of 2020 to US$ 49.38 mln for 9 months of 2021. Thereof, European properties acquired during 2020 generated a total NRI of US$ 7.48 mln (9 months of 2020: US$ 2.67 mln). The performance of the other European properties, as well as Russian properties remained almost unchanged as compared to the same period of 2020.During Q3 20

NEXTENSA NV/SA: SHARES – VOTING RIGHTS AND DENOMINATOR PUBLICATION IN COMPLIANCE WITH ART. 15 OF THE LAW OF 2 MAY 2007 (THE TRANSPARENCY ACT)30.11.2021 17:40:00 CET | Press release

NEXTENSA NV/SA: SHARES – VOTING RIGHTS AND DENOMINATOR PUBLICATION IN COMPLIANCE WITH ART. 15 OF THE LAW OF 2 MAY 2007 (THE TRANSPARENCY ACT) As previously announced1, the EGM of 19 July 2021 introduced the double voting right (loyalty voting right), in accordance with article 7:53 of the Code of Companies and Associations. This means, in accordance with article 28 of the articles of association, that double voting rights are granted to each fully paid-up share that has been continuously registered in the share register in the name of the same shareholder for at least two years. The other shares give right to one vote. The two-year period starts from the date of registration of the nominative shares in the share register. In compliance with article 15 of the aforementioned Transparency Act, every month the Company must publish, on its website and by means of a press release, the total capital, the changes to the total number of voting securities and the total number of voting rights, i

Change in the number of shares and votes in Sinch AB (publ)30.11.2021 17:35:00 CET | Press release

Stockholm, Sweden – November 30, 2021 – Sinch AB (publ), a global leader in cloud communications for mobile customer engagement, today announced that the number of shares and votes in Sinch AB (publ), registration number 556882-8908 (“Sinch”), amounts to 747,480,901 on November 30, 2021. The change in the number of shares and votes in November is a result of the issue of totally 1,317,537 new shares in connection with the closing of the acquisitions of MessageMedia and MessengerPeople, as previously communicated. For further information, please contact Ola Elmeland Investor Relations Director Mobile: +46 721 43 34 59 E-mail: investors@sinch.com Thomas Heath Chief Strategy Officer & Head of Investor Relations Mobile: +46 722 45 50 55 E-mail: investors@sinch.com About Sinch Sinch brings businesses and people closer with tools enabling personal engagement. Its leading cloud communications platform lets businesses reach every mobile phone on the planet, in seconds or less, through mobile m

Ändring av antalet aktier och röster i Sinch AB (publ)30.11.2021 17:35:00 CET | Pressemelding

Stockholm, Sverige – 30 november 2021 – Sinch AB (publ), en ledande global leverantör av molntjänster för kundinteraktion via mobilen, meddelade idag att antalet aktier och röster i Sinch AB (publ), org.nr 556882–8908 (”Sinch”), uppgår till 747 480 901 den 30 november 2021. Förändringen av antal aktier och röster under november har föranletts av att totalt 1 317 537 nya aktier har emitterats i samband med slutförandet av förvärven av MessageMedia och MessengerPeople, som tidigare har kommunicerats. För mer information, vänligen kontakta Ola Elmeland Investor Relations Director Mobile: +46 721 43 34 59 E-mail: investors@sinch.com Thomas Heath Chief Strategy Officer & Head of Investor Relations Mobile: +46 722 45 50 55 E-mail: investors@sinch.com Om Sinch Sinch utvecklar digitala verktyg som möjliggör en personlig interaktion mellan företag och individer. Med Sinch molnbaserade kommunikationsplattform kan företag nå världens alla mobiltelefoner – inom en eller ett par sekunder – via medd

GivingTuesday: NOVA Chemicals Expands Total COVID-19 Relief to US$1.25M with Additional Gifts30.11.2021 16:40:00 CET | Press release

Programs supporting mental health, food security, and overall community resiliency receive funding through corporate giving campaign Calgary, Alberta, Canada , Nov. 30, 2021 (GLOBE NEWSWIRE) -- NOVA Chemicals Corporation, 1000 Seventh Avenue S.W., Calgary, Alberta, Canada T2P 5L5 www.novachemicals.com | 403.750.3600 tel | 403.269.7410 fax NOVA Chemicals Corporation (“NOVA Chemicals”) today announced an additional US$600,000 commitment in COVID-19-related supports across our operational regions, bringing the total amount given for pandemic relief to US$1.25M, as part of efforts to meaningfully give back to our neighbors and their communities. “While we continue to see positive momentum toward a world with higher vaccination rates and fewer restrictions, the impacts felt by the pandemic will unfortunately have lasting effects,” said Mona Jasinski, SVP HR and Communications, NOVA Chemicals. “I am proud of NOVA’s commitment to ensuring there is food on the table for tens of thousands of pe

KICKS CHOSES WESTPAY AS PROVIDER OF PAYMENT SOLUTIONS30.11.2021 16:40:00 CET | Press release

Westpay has today signed an agreement with Kicks regarding payment solutions in Sweden, Norway, and Finland. The solution enables card payments as well as Swish, Vipps, Mobile Pay, and other alternative payment methods. The value of the initial order amounts close to SEK 4 million during the coming three years. - Kicks is a solid and well-known brand in the Nordics. The customer experience is a key element in their success. Westpay and our solutions enable all the features and solutions they need to level up their overall offering. They made an accurate and relevant assessment and knew that their payment solution was required to support them in their ongoing business today as well as tomorrow. Now, they have a future-proof solution that they can rely on in their future journey, says Hans Edin, CCO at Westpay. KICKS is the Nordic region's leading beauty chain and offers a holistic concept in makeup, fragrance, skin care and hair care. With experts in 250 stores in Sweden, Norway and Fin